Added to YB: 2026-02-16
Pitch date: 2025-12-04
DERM [bullish]
Journey Medical Corporation
-13.69%
current return
Author Info
No bio for this author
Company Info
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Market Cap
$177.0M
Pitch Price
$7.89
Price Target
N/A
Dividend
N/A
EV/EBITDA
119.72
P/E
-28.15
EV/Sales
2.60
Sector
Pharmaceuticals
Category
growth
Journey Medical Corporation - $DERM
DERM: Emrosi launched April 2025, first oral rosacea drug in 20yrs showing superiority vs Oracea ($311M sales) in Phase 3: 62.7% vs 39% IGA success, 19 vs 14.8 lesion reduction. Base $55M rev business break-even. Mgmt targets $200M+ US peak sales, patents to 2039. Early traction: 34K scripts, 2,720 prescribers by Oct'25. Risk: execution, generics from 2027, payer dynamics.
Read full article (12 min)